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Abstract
Antiretroviral therapy (ART) requires nearly perfect adherence to be effective. This study aims to 
identify key factors identified by HIV-infected adolescents on ART as contributing to medication 
adherence in western Kenya. Using a qualitative study design, three adolescent focus groups 
discussions were conducted at an urban and rural clinic site in western Kenya. The study 
population included HIV-infected adolescents receiving ART through the USAID-AMPATH HIV 
care system. A trained facilitator conducted groups in Kiswahili using a semi-structured interview 
guide probing multiple aspects of experience of taking medicines. Transcribed focus group 
dialogues were analyzed using constant comparison, progressive coding, and triangulation. The 
adolescents described a context of negative societal beliefs about HIV, necessitating a lifestyle of 
secrecy and minimizing the information shared about HIV or ART. Assessing and addressing 
adolescents’ fears and behaviors regarding medication secrecy and disclosure may enable more 
accurate monitoring of adherence and development of intervention strategies.
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According to the World Health Organization 2008 Global Summary of AIDS, 33.4 million 
people worldwide are living with AIDS, with 2.1 million of those being children under the 
age of 15, and 1.8 million of these children live in sub-Saharan Africa (World Health 
Organization, 2009). Since the majority of the disease burden of HIV is within sub-Saharan 
Africa, where 280,000 children die each year from HIV, it is important assess what is needed 
to treat HIV in children in this region.
Combination antiretroviral therapy (ART) has proven to be effective in slowing the rate of 
progression from HIV to AIDS (J. E. Haberer et al., 2011; Martino et al., 2011). A 
fundamental challenge is sustaining the high level of ART adherence necessary to achieve 
long-term suppression of the viral load (Gibb et al., 2003; J. E. Haberer et al., 2011). Non-
adherence can lead to a poor virological response and drug resistant strains, increasing HIV 
morbidity and mortality (Nyandiko et al., 2006). Moreover, access to second-line and third-
line therapies for HIV is often limited, making it even more important to adhere to and 
preserve the first-line regimen (J. Haberer & Mellins, 2009; Nyandiko et al., 2006).
Factors impacting children’s adherence to ART in sub-Saharan Africa, particularly the 
adherence of perinatally infected adolescents, are not yet well understood. A systematic 
review on pediatric ART adherence in resource-limited settings found children’s ART 
adherence ranged from 49% to 100%, with 76% of articles reporting >75% adherence 
(AUTHOR, 2008). However, most of these settings have not provided treatment for very 
long. Studies from other pediatric diseases, such as pediatric cancer, suggest that adherence 
becomes increasingly challenging over time, especially as children approach adolescence 
(Davies, Whitsett, Bruce, & McCarthy, 2002). Research examining non-adherence to ART 
suggests that family dynamics, social factors, and treatment fatigue have all been related to 
adherence patterns (J. Haberer & Mellins, 2009; AUTHOR, 2008). Disclosure may play a 
role in adherence as children who do not know why they are taking medications may 
struggle with why they should comply with treatment or with unanswered questions about 
their condition (J. Haberer & Mellins, 2009). In a recent qualitative study, caregivers 
reported that drug characteristics such as the taste, palatability, and volume of drug(s) were a 
barrier to adherence, but their social situations and persistent fear of disclosure were also 
consistent barriers to adherence (Gibb et al., 2003). The cultural context of the family, 
neighborhood, tribe, or church can impact the experience of having a child on ART 
(AUTHOR., 2009). For example, one study found an association between changes in 
residence and ART non-adherence (J. E. Haberer et al., 2011). Orphans are also more likely 
to have ART non-adherence, potentially because of multiple differences in their cultural 
context (AUTHOR, 2008). For instance, orphaned children in places with limited social 
services often end up managing their own ART regimens, which may demand more 
responsibility than they are developmentally ready to handle (J. Haberer & Mellins, 2009). 
Differences in orphans’ adherence to clinic visits compared to adherence to ART may reflect 
how orphans’ caregivers prioritize the social services and support they receive as part of a 
clinic visit over the actual health of the child (AUTHOR, 2008).
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Few studies of pediatric ART adherence in sub-Saharan Africa have included self-reported 
data from the child’s perspective. Rich, self-reported data from older children and 
adolescents could be especially useful for understanding the experience of adherence for 
children in a particular cultural context. The perspective of adolescents might be particularly 
important since there is some evidence that children’s age impacts their ART adherence, 
though studies showing mixed results (Carlucci et al., 2008; J. E. Haberer et al., 2011; 
Nyandiko et al., 2006; Orikiiriza et al., 2010). Adolescence can be a challenging time 
developmentally even when a child does not have a chronic disease. For children infected 
with HIV, even those who were highly adherent to ART at younger ages often report 
adherence problems during adolescence (Williams et al., 2006). The long-term importance 
of ART adherence may be lost to other short-term priorities for the adolescent, such as 
appearance, social/sexual relationships, and overall identity development (J. Haberer & 
Mellins, 2009). There is much to learn about the course of ART adherence over time for 
children in Africa as the first cohorts of perinatally infected children begin to enter 
adolescence.
Qualitative research can offer a beneficial starting point to guide the understanding of a 
complex health behavior, particularly within a given cultural framework and from the 
perspective of the participants. The main objective of this qualitative study was to identify 
the key factors contributing to pediatric ART adherence in western Kenya from the 
perspective of perinatally infected adolescents.
METHODS
Setting
This study was conducted in western Kenya within the USAID-Academic Model Providing 
Access to Healthcare partnership (AMPATH). AMPATH grew out of a partnership 
established in 1989 between Indiana University School of Medicine, Moi University School 
of Medicine, and Moi Teaching and Referral Hospital (MTRH) (Quigley, 2009). Since 2001, 
AMPATH has been a model HIV care system for resource-limited settings (Einterz et al., 
2007; Quigley, 2009). The AMPATH clinical care system operates in Kenya, a country with 
a national HIV prevalence of 7.8%, where over 1.4 million persons live with HIV, including 
150,000 children (2007 Kenya AIDS Indicatory Survey, 2008). As of October 1, 2012, 
AMPATH has enrolled more than 140,000 patients in western Kenya, and currently follows 
more than 75,000 patients (including more than 24,500 children) at 25 urban and rural clinic 
locations and 30 satellites. AMPATH provides free ART to all patients qualifying for 
therapy, as well as comprehensive nutrition services, psychosocial support, and economic 
development training. The adolescent-focused portion of this study was conducted within 
two AMPATH clinics. One site was the urban referral center in Eldoret, which has been in 
operation since November 2001 on the grounds of MTRH. As of October 1, 2012, the 
MTRH clinic cares for a total of 27,611 patients. Of those patients, 5,672 are children 14 
years of age or younger, and 1,037 children at MTRH are currently on ART. The other site 
was an AMPATH HIV clinic at a rural heath center location in western Kenya, which cares 
for 249 children, of whom 140 are on ART.
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A convenience sample of HIV-infected adolescents on ART was recruited from the two 
AMPATH pediatric HIV clinics described above. Participants were eligible if they were 
enrolled in the AMPATH HIV clinic at MTRH or the rural health center, if they were 
between the ages of 10 and 16 years, if they were HIV-infected with no evidence of 
horizontal transmission, and if they were currently on ART. The WHO definition of 
adolescents as children ages 10 and above was used to define the group of eligible children 
(World Health Organization, 2008). Adolescents as young as 14 years, but particularly those 
above 16 years of age are treated in the adult AMPATH clinics, and so they were not 
included in this sample as their care experience is likely different. Eligible subjects were 
identified by examination of the HIV clinics’ registration data, contacted initially by the 
clinic, and then by study personnel who explained the purpose of the study and obtained 
informed consent from the parent or guardian and assent from the children or adolescents. 
Participants were not required to know their HIV status, but clinic personnel only 
approached eligible children who already knew they were HIV positive. Patients were 
excluded if there was any physical or mental incapacity leading to an inability to understand 
the study.
Study Design
Focus groups and individual interviews were used to elicit data from HIV-infected children 
taking ART in the AMPATH care system. Interviews were initially used in order to establish 
a more comprehensive understanding of the data and to assess the impact of the questions. 
Both techniques were used, following the theory that the group discussions allowed for 
amplification of the shared perspectives and themes, while the individual interviews 
potentially lessened biasing effects from social norms (Krueger, 1988; Morgan DL, 1998; 
Sankar, Golin, Simoni, Luborsky, & Pearson, 2006).
Three focus groups and three individual interviews were conducted using the same script of 
semi-structured interview questions in Kiswahili. Each of the focus groups consisted of six 
to eight individuals, with one girls’ group and one boys’ group at MTRH and one mixed 
gender group at an AMPATH rural health center HIV clinic. The focus groups at MTRH 
were stratified by sex because interactions between sexes in adolescents were thought to 
potentially complicate group dynamics (Krueger, 1988). The group at the rural health center 
clinic involved a group of adolescents who had consistently been meeting as a support group 
and who were considered comfortable interacting in a mixed group. The focus groups and 
interviews were conducted in Kiswahili, one of two national languages in Kenya (AUTHOR, 
2010). The groups and interviews were conducted between March 1 and November 30, 
2007. The focus groups at MTRH were held in a classroom at the AMPATH referral centre, 
and the focus group at the rural health clinic was held in a large room that is available for 
training and which is the usual location of the pediatric support group at that facility. The 
individual interviews were held in a private research office within each facility. A trained 
facilitator used identically prepared interview guides, containing open-ended questions to 
solicit responses during a two-hour session for focus groups and a one-hour session for 
individual interviews (AUTHOR., 2010). Each focus group was led by a Kenyan research 
assistant with experience facilitating focus groups in this setting and in conducting 
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interviews involving sensitive health behavior issues. The facilitator was fluent in English 
and Kiswahili, the primary languages needed to conduct the focus groups in this population. 
All data regarding the caregivers and their children were based on the participants’ self-
reports. All of the participants granted permission to digitally record the sessions to allow 
for later transcription. All of theses digital recordings were transcribed and translated into 
English by a trained translator. The principal investigator (R.C.V.) was also present at the 
focus groups and took detailed field notes. Basic demographic information about the HIV-
infected child, the family composition, the time and nature of diagnosis, and any associated 
medical diagnoses were also collected. The translation into English was done by a native 
Kiswahili speaker with official WHO certification in translation. Both the Kiswahili 
transcripts and the English translations were independently compared by three individuals: 
the certified translator, the coinvestigator who had conducted the original focus groups 
(E.G.W., who is a native Kiswahili speaker and fluent in English), and by an additional 
coinvestigator (W.M.N.) who is a native Kiswahili speaker and fluent in English. The 
analysis was carried out using the English versions of the transcripts by one of the members 
of the investigative team who was bilingual and had reviewed the translations (W.M.N.), by 
the principal investigator (R.C.V.) who has learned Kiswahili as a second language, but only 
worked with the English translations of the transcripts, and by an investigator who worked 
only in English (C.J.Z.).
The questions used in the focus groups and interviews were based upon review of the 
literature, input of local health care providers, and initial pretesting with a series of five, in-
depth key informant interviews with adults that were conducted within subjects’ homes 
(AUTHOR., 2010). Questions were modified for children after three pediatric interviews. 
Topics covered during the encounter included: cultural context of HIV treatment, medication 
handling, beliefs about medications, interactions around medicines, and barriers to 
adherence. The scripted interview guide is available upon request.
This study was approved by the Institutional Review Board of Indiana University in 
Indianapolis, Indiana and by the Institutional Research Ethics Committee of Moi University 
School of Medicine and Moi Teaching and Referral Hospital in Eldoret, Kenya.
Analysis
A system of manual, progressive coding of the transcripts was used to identify emerging 
central concepts. Using open-coding methodology, the transcripts were manually coded in 
an initial stage of constant comparative analyses, with two separate investigators (R.C.V. and 
C.J.Z) working manually, line-by-line to analyze each transcribed page of informant data. 
Each investigator extracted themes independently and then collaborated to compare results. 
The two analysts processed the data several times before reaching a consensus on the 
emerging themes. Following development of the thematic structure, a local Kenyan 
investigator (W.M.N.) reviewed the coding and analysis for an insider perspective on the 
data interpretation. Axial coding, the process of relating categories to their subcategories and 
linking them together at the level of properties and dimensions, was used to organize themes 
into ‘causal’ relationships (Glaser B, 1967; Strauss A, 1990; AUTHOR, 2010). Analysts 
were able to form practical hypothesis and concepts from the data, which lead to the 
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development of a theoretical framework to describe key aspects in the experience of taking 
ART from a child’s perspective. Selected quotations were used to illustrate themes 
(AUTHOR, 2010). Triangulation or verification was incorporated on several levels. First, we 
analyzed and compared transcript data from multiple focus groups. Second, independent 
reading, coding, comparison, and data visualization were performed by three investigators 
(R.C.V., C.J.Z., W.M.N.). Finally, we incorporated two sources of peer debriefing and peer 
checking of transcripts, coding strategies, and themes (T.S.I., D.G.M.). The peer debriefing 
and peer checking primarily refined the organizational structure and conceptual map created 
from the data, refining the organization of the causal relationships and confirming the 
prominent themes.
Results
Twenty-three adolescents participated in the focus groups. They ranged in age from 10 to 16 
years (mean 13.2 years.) Eleven were female and 12 were male. All were on ART and knew 
their HIV status, but their time on ART ranged from one month to four years. Most lived 
their grandparents (30.4%) or with an aunt or uncle (21.7%), and only 2 had both biological 
parents alive. Among the 23 adolescents, the most prominent themes related to the 
experience of taking medication were secrecy and how secrecy and other barriers hindered 
their adherence to ART (see Table 1). They described common beliefs about HIV disease 
and its treatment, but their discussions rapidly focused around secrecy and other issues 
shaping their ability to adhere to ART.
Beliefs about HIV disease and its treatment
The children described being surrounded by many negative societal beliefs about HIV, its 
transmission and its treatment, most of which were not scientifically accurate.
Participants in this study reported hearing that HIV is a curse or that it is a disease that hides 
in the bones, and that the antiretroviral medicines are manufactured from the parts of dead 
people. Even among those who had heard statements supporting the efficacy of ART, this 
was not necessarily viewed positively. One child said that he heard HIV medicines are 
corrupt because they impede the ability to differentiate between sick and healthy people, 
stating, “You may see a girl and think she is okay. You don’t know whether she is sick or she 
is okay so you may end up having sex with her and you get infected”. The adolescents also 
reported hearing inaccurate, fearful claims about how HIV was transmitted. For instance, 
some participants had been told that you can acquire HIV by sitting beside someone with the 
virus:
“Some say that if you have the virus and then I come and sit beside you, you will be 
transmitting the virus to the other person’s body. Then they get the disease so they 
would not want to sit next to you.”
They also reported that traditional, complementary, or alternative medicines were often seen 
as a first-line of treatment for HIV or HIV-related symptoms. Both younger and older 
children described using herbs, fruits, and teas, both orally and topically, as well as more 
unusual recommendations such as drinking urine:
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“I used those herbs and I have even drunk urine because there is someone who 
came and lied to us that drinking urine can heal HIV. So I just used to drink urine 
for 3 months.”
Using these alternative therapies was typically reported as practices that were tried before 
beginning ART, although some adolescents reported the continued use of alternative 
therapies while on ART.
Secrecy
Secrecy related to HIV status and HIV treatment was repeated throughout the data as a 
central theme, and was described as way of life for these adolescents. Nearly all of the 
participants in the focus groups described the importance of keeping their disease secret, 
which had implications for their ART adherence. HIV-infected children strive to maintain 
secrecy within their families, peer groups, neighborhoods, and school. They reported how 
their lives were shaped to ensure that as few people as possible know about their disease; to 
cautiously control information-sharing; and to take, store, and dispose of medications in 
secrecy.
Minimize the number of people who know
One aspect of keeping their HIV status a secret was only telling others about anything 
related to HIV care when it was absolutely necessary. Many of the participants reported that 
only a small number of immediate family members who were directly involved in their care, 
such as a parent, grandparent, or sibling, were aware of the child’s positive HIV status and 
use of medications. They often stated that no one at school or in their community knew 
about their disease, and not even all members of the immediate family might know about the 
HIV diagnosis. Sometimes the child’s school teacher will be included in this intimate group 
of people who know about their disease because they needed permission to attend doctor 
appointments when school is in session.
Beware of the risks of sharing information
Generally, positive HIV status is information guarded very closely by the adolescent and the 
caregiver. Some information-sharing may be done to gain more support in caring for the 
child or when necessary to maintain HIV treatment; however, participants reported an 
ongoing emphasis on minimizing information-sharing. Taking medication in front of other 
people was seen as a behavior that might convey information that would generate questions 
and accusations about HIV:
“If you use the ARVs where a visitor is, they will start asking you so many 
questions, and they want to know why you are using [the drugs]. Sometimes, if 
someone just sees the medicine, they will not want to ask, they will just know that 
there is a person in that family that uses those drugs. So it will spread and people 
will know even without being told.”
Not taking medication in front of other people was prioritized over the need to take 
medications on time or to take them every day; adolescents believed withholding 
information was more important than adherence.
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Negative consequences to information-sharing were the primary reason participants felt that 
secrecy needed to be a major aspect of their lives and their behaviors related to HIV care. As 
demonstrated by the following excerpts, children were fearful that disclosing HIV status to 
others would lead to rejection, discrimination, and blame:
“It is not good for people to know because when some know, they go and spread it 
out and don’t want to stay with you.”
“You are not supposed to tell people that you are using those drugs because they 
will broadcast that you have HIV and are using those drugs and everyone will 
know. People will start looking down upon you [and] avoid you. You can’t even 
take water in someone’s house; they will not give [it to] you, and say that you are 
sick and will infect them.”
Covert storage of medications
Hiding medication from public view was another key component of keeping HIV status 
secret, which also had implications for medication adherence. In conjunction with viewing 
HIV as a stigmatized disease, the adolescents reported that they and their families feared that 
neighbors, extended family members, or other people in the community might recognize 
their medicines as a sign of their HIV status unless they were concealed carefully. If the 
child’s medicine was found or seen, they felt that their HIV status could be exposed to their 
peers or to the entire community, which was anticipated to result in the negative 
consequences.
To avoid having the medications seen, respondents reported taking care to keep their 
medicine in a safe place in the house. While many of the participants lived in very simple, 
shared, one-room homes, medications were kept in whatever the most secure and hidden 
place in the home might be. Some common hiding locations included the “cupboard”, 
“bedroom”, “wardrobe”, and a “secure box.” One child expressed the importance of keeping 
his medication hidden for fear of recognition:
“Because most of our family people are doctors, for example my aunt. Sometimes 
she can come [over] and maybe she knows the medicines so I don’t want her to 
know. That’s why I lock and put the key where no one can reach.”
Behaviors for keeping their medicines secret even extended to covertly destroying the empty 
medicine bottles:
“Like the empty medicine bottles, we pile them in a big polythene bag. Then my 
mother goes to burn them later on when there are no people around. During the 
holidays, she burns them in the compost pit.”
In summary, the need for secrecy plays an important role in the life of an HIV-infected 
adolescent on ART in western Kenya. Because of their fear of disclosure and subsequent 
stigmatization, children on ART and their families limit who is told about their HIV 
infection and how much information they share with others, while taking precautions not to 
take medicines in front of others or to have their medicines discovered by other.
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This qualitative study revealed several factors shaping the context in which adolescents 
maintain ART in western Kenya. In addition to the dominant concerns about secrecy, which 
shaped many of their experiences related to their ART, participants described how adherence 
could be impacted by their responsibility for taking medicines, their experience with and 
perceptions of barriers to adherence, and their hesitancy in communicating about non-
adherence with caregivers and healthcare providers.
Responsibility for medications
Many of the adolescents indicated that they have no one who helps them to remember or to 
take their medicines. Those receiving help commonly specified that it was from a parent, 
grandparent or sibling. In many cases, the caregiver may be “reminding” the child to take the 
medicine, especially “when [the child] comes home late from school” or around the time a 
dose would be expected. However, the adolescents acknowledge personal responsibility for 
actually taking the medicine: “Maybe [have help with] reminding, but taking, I do on my 
own.”
They use various methods to remember to take their medication, often employing a clock, 
phone alarm, or a watch. Others discussed that knowledge of their disease status has 
“programmed [their mind] to remember,” even suggesting that there is an internal “clock 
that is always set” that reminds them.
The adolescents frequently suggested that disclosure had a strong impact on adherence. 
Learning of one’s own HIV status was often described as an important factor in assuming 
responsibility for their medicines and in subsequently improving their own adherence to 
ART. As two adolescents described:
“You remember the day you were shocked when they told you that you have this 
dangerous disease, and you know that you have to take the medicine.”
“I remember when I became shocked when they tell me that I have this dangerous 
disease. Then something comes to your mind, you have to take your drugs or you 
will die.”
Barriers to adherence
The children in this study acknowledged numerous barriers to adherence. Some commonly 
reported issues included “forgetting,” “not feeling sick,” “delaying taking [medicine] in 
front of others,” and “oversleeping.” Delays or missed doses related to not having the 
medicines with them or not planning for absences were also frequently reported, as depicted 
by the following excerpts:
“You have gone on a journey, and you are sure you are coming home that day, so 
there is no need of carrying the drugs. So when you reach there, something happens 
to the vehicle and you can’t travel that day or you come back very late. Such things 
can make you miss the drugs for 2 days or more.”
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“I may delay at school due to rain or meeting, and I reach home late. I can’t carry 
the medicine to school to take at six because I will be known”.
“If I go on a journey and it gets late, then I delay taking the meds.”
These quotes also reinforce how the adolescents consistently strive to maintain secrecy by 
not taking their medicines along on trips or to school. Their efforts to maintain secrecy could 
also impair adherence because of their reluctance to take medicines in front of other people:
“We are many in the house and it is only the parents who know [that I have HIV], 
so if they are not there and the others see me removing those drugs, they will be 
anxious to know what they are for and why I am taking them. So it forces me to 
delay taking the drugs if they are around. At times, I even forget and the time for 
taking the drugs passes. I swallow [the drugs] late.”
The participants also described being overwhelmed by the requirements of their treatment 
regimen. Fatigue with taking medications became a barrier to adherence as they grew tired 
with the duration of their treatment and the number of medicines required:
“Maybe if you have taken for a long time, and you are not getting well, you give up 
and get tired of taking the drugs.”
“Others see the medicine as being many, so they may throw it away.”
They described several additional issues associated with the pill burden, noting that the pills 
can be “too big in size so they get stuck in the throat” or “syrups may be bitter and one may 
vomit.” One child stated that there are simply “too many” pills that “you opt not to take 
them all” and only “take the ones for the disease you are suffering from at the time and leave 
the normal ones.” Even measuring out the medication was noted as a problem at times, 
particularly for the liquid formulations where the spoon may “tilt a bit and [it] spills.”
Interpersonal conflicts were presented as another barrier to the adolescents’ adherence to 
ART. Participants described how their behavior regarding their medications reflected their 
feelings about their interpersonal relationships. Taking or not taking their medications could 
be used as a form of rebellion with their caregivers:
“You forget to take the drugs in the morning and in the evening you delay a bit. 
Then the guardian quarrels you, abuses you, and forces you to take them. So you 
get angry and say I am not even taking them. Let them stay and the day ends like 
so.”
Adherence and behaviors around the medications were also used as a mechanism for these 
older children to express their emotions, particularly related to their family situations and 
their illness status. Participants reported deciding not to take their medication because they 
felt like they were not getting support from their family or as a way to externalize their 
internal emotional state:
“My aunt tells me to ‘go away -- your mother died of it and now you are bringing it 
to me; you are just disturbing me, you better go to another place.’ I felt like she is 
now being harsh to me because of that disease. Okay, let me die and the medicine 
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go to hell because I felt it was like nothing. It was now worthless for me to take the 
medicine.”
While some participants described not taking medications as a response to harsh treatment, 
others reported receiving severe punishments because they had not been adherent to their 
ART. Some children admitted to being “beaten very badly” and “treated harshly” as 
punishment for delaying or forgetting to take medication.
Hesitancy in reporting non-adherence
Although the adolescents freely described challenges with ART adherence in the setting of 
the focus groups, they also expressed not feeling comfortable communicating these issues to 
their healthcare providers in the course of their routine clinical care. Adolescents will often 
minimize the extent of their non-adherence when communicating with clinic personnel:
“I may have missed for one week so I will just tell them I’ve missed for 3 days.” They 
attributed this hesitancy in reporting non-adherence to discomfort or unfamiliarity with the 
medical staff, as well as to a fear of abuse by the caregiver if their non-adherence was 
discovered:
“I fear. When [clinicians] are new and I don’t know them, I fear to tell them.”
“When I come with my guardian and we see the doctor together, you fear telling 
the doctor because the guardian may abuse you or do a terrible thing.”
Despite their reluctance to communicate adherence problems, the participants in this study 
were under the impression that the doctors “can just tell” when a child is lying and would be 
able to recognize signs of illness and non-adherence, such as “rashes or CD4 count,” when 
they are not adhering. One adolescent suggested that the doctors need to be more alert to the 
child’s mannerisms:
“When you are asking them, you will see their reactions, either worried, fidgeting, 
thinking of what to say. They are asking themselves can I say the truth or not.”
DISCUSSION
HIV-infected adolescents on ART in western Kenya describe many layers of secrecy related 
to their disease and how this secrecy and other challenges impact their adherence to ART. 
Secrecy, stealth, and covert behaviors have become a way of life for them, as they believe 
that they must keep their disease status hidden. Adolescents fear that they will be 
discriminated against or abandoned by family and peers if their HIV status is found out. In 
efforts to avoid the stigmatization associated with HIV, adolescents only communicate their 
status to a minimal number of people, largely on a need-to-know basis.
This emphasis on secrecy pervades the adolescents’ behaviors related to the HIV therapy. 
Medications are stored in very guarded locations, preventing household members and 
visitors from easily finding them. These older children are very conscientious about only 
taking their medications when others are not around to observe them. They take deliberate 
actions to reduce the possibility of information-sharing -- not carrying medicines with them, 
not taking the medicines in front of other people, and handling medication procurement, 
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storage, dosing, and disposal with great care. Consequently, as reported by the adolescents, 
the actions to reduce information-sharing, often cause delayed or missed doses. Other 
barriers to adherence include the pill burden (quantity, size, taste, side effects), forgetting, 
medication fatigue, and lack of planning to bring medication on journeys away from home. 
Behavior around the medicines was also embedded within their interpersonal relationships. 
The adolescents reported refusing to take medicines in an attempt to punish their caregivers 
or using their adherence as leverage in conflicts or as a reflection of their emotional state. 
Abandoning the medicines was recognized as an action reflecting their own feelings of 
abandonment. Despite the many challenges to medication adherence freely described in the 
focus groups, these adolescents were hesitant to provide accurate reports of missed doses in 
clinical settings, citing the redundancy of lectures on adherence, unfamiliarity with their 
medical providers, and fear of harsh repercussions from caregivers.
As cited by other studies, keeping HIV status secret can generate substantial barriers to 
adherence, including stress and inadequate support (Marhefka, Tepper, Brown, & Farley, 
2006; Mellins, Brackis-Cott, Dolezal, & Abrams, 2004; Polisset, Ametonou, Arrive, Aho, & 
Perez, 2009). Adolescents carry a great burden of stress through their worry and their 
considerable measures to ensure their secret is safe. Their support network may be reduced 
by only relying on themselves and their caregiver. In contrast, disclosure of the child’s HIV 
status to family and the community might help reduce stress and mobilize support for 
adherence (J. Haberer & Mellins, 2009; AUTHOR, 2010). For example, some studies 
suggest that disclosure to school nurses could be beneficial in maintaining adherence, 
especially when dosing must occur during school hours (J. Haberer & Mellins, 2009). 
Although disclosure to others has been associated with good adherence in settings like 
Uganda there is always the possibility of stigma and discrimination, which leads to 
reluctance in seeking support from others (Brouwer, Lok, Wolffers, & Sebagalls, 2000; J. 
Haberer & Mellins, 2009). Informing children of their own HIV status has been shown to 
improve adherence in several studies (J. Haberer & Mellins, 2009; AUTHOR, 2010; 
AUTHOR, 2008; Wiener, Mellins, Marhefka, & Battles, 2007). However, disclosure of HIV 
status to a child can be a complex process for families, as they fear not only the stigma 
associated with the diagnosis, as well as the potential for emotional distress for the child or 
for parental guilt about mother-to-child transmission (Wiener et al., 2007). These findings 
from western Kenya suggest that guiding families through the process of disclosure to 
children and then engaging thoughtfully in disclosure to even one or two other people may 
enhance their psychosocial support, possibly sustaining and improving adherence.
As demonstrated in this study, one major aspect of protecting information-sharing involves 
delaying doses when other people might be around. Consistent with previous findings in 
Kenya, pediatric adherence is very much shaped by the people around the child and the 
family, by the information shared with these people, and by their responses to that 
information (AUTHOR., 2009). While these findings may be particularly relevant to 
resource-limited settings, a study involving caregivers of HIV-infected children throughout 
Europe reported similar reasons for why the child missed doses, including “visiting relatives 
over the weekend,” “visitors in the house,” and “because he is visiting or out with friends” 
(Gibb et al., 2003). While disclosure to others carries serious risks of stigma or 
discrimination for HIV-infected families, delaying or missing doses could result in 
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detrimental consequences to their health, leading to viral resistance and treatment failure. In 
these instances, examining the deep emphasis on secrecy and considering selective 
disclosure to others may improve adherence by enabling children and adolescents to find 
ways to take their medicines even when other people might be around. Efforts to combat the 
strong HIV stigma in this culture may be another important intervention to enhance and 
support pediatric ART adherence. Providing communities with accurate information on how 
the disease is acquired and transmitted may decrease stigma and debunk currently held 
misperceptions about HIV.
Many of the participants in this study reported taking sole responsibility over their 
medication regimen. Families may not understand all the challenges associated with long-
term adherence and inaccurately assess the child’s capacity for this responsibility (Gibb et 
al., 2003). Varying levels of maturity or developmental delays could inhibit the child’s 
ability to bear the responsibility alone and adherence could suffer (Gibb et al., 2003). 
Increased support from the family, and shared responsibility can have a positive effect on 
adherence (Mellins et al., 2004; Naar-King et al., 2009). Assessing the extent to which 
families offer adherence support to older children, even as the adolescents make 
developmentally appropriate gains in their autonomy for their medical treatment, may be 
important to understanding their adherence challenges.
There are several limitations present in this study. Convenience sampling from two clinics in 
western Kenya and a small sample size may limit the generalizability of the data to other 
populations and geographical regions. Nonetheless, this method was chosen to collect rich 
contextual data to better direct further research. Moreover, the sample size is not atypical for 
a qualitative study, and good thematic saturation was found. In addition, the findings of these 
focus groups were very consistent when compared with a much larger number of interviews 
and focus groups done with parents and caregivers from the same setting, offering further 
validation for how these factors impact pediatric ART adherence within western Kenya. 
Another limitation is that, while the focus group methodology invites an open group 
discussion, it is difficult to induce a response from every participant on each topic. This 
could bias the results if only certain participants engaged in the conversation. Nonetheless, 
the study team attempted to create an open atmosphere within the groups, where adolescents 
were all invited to share. In both the groups and the individual interviews, the participants 
did not hesitate to describe sensitive topics such as non-adherence and interpersonal 
conflicts. In fact, the group discussions contained even more of this information. Although 
there are limitations to this study, the data provide a broad prospective of lived experiences 
from adolescents in a resource-limited setting, which may be more representative of the 
experience in similar settings in sub-Saharan Africa than studies done in resource-rich areas.
This qualitative study provides insight into understanding HIV-infected adolescents’ 
experience of taking medicine in western Kenya. The study participants emphasized the 
importance of secrecy to managing life with HIV and commonly experienced barriers to 
adherence. The data presented in this study can educate and alert practitioners about 
problematic issues that HIV-infected children and adolescents are facing, but may not be 
comfortable admitting, and to foster open discussion of such issues during clinic visits. 
Combating stigma and lessening the need for secrecy may be important interventions to 
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maintain pediatric ART over the long-term. Future studies could use these data as a 
foundation to explore interventions that may reduce the barriers to pediatric ART adherence 
in resource-limited settings and promote sustained adherence.
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Table I
Adolescent-Reported Themes for ART Adherence
Emerging Themes Sample Excerpts from Focus Group
Secrecy
Minimize the number of people that 
know
“My head teacher and class teacher know because I have to ask for permission to come to clinic.”
Covert storage of medication “Mine I keep in my box and lock and put my key inside my clothes…”
Beware of the risk of information-
sharing
“Sometimes if you use [medicines] when people are seeing you, they go out and broadcast you, they 
spread that you use.” HIV medicine.”
Other Barriers to Adherence
Responsibility for medication 
adherence
“Maybe reminding me sometimes when I come home late from school. May be reminding, but taking I 
do it on my own.”
Pill burden “They are too big in size so they get stuck in the throat.”
Interpersonal conflict “You forget to take the drugs in the morning and in the evening you delay a bit. Then the guardian 
quarrels you, abuses you, and forces you to take them. So you get angry and say I am not even taking 
them. Let them stay and the day ends like so.”
Just forgetting to take medications “At times you just forget to take your medicines.”
Delaying doses because of school or 
work
“I reach home late and I can’t carry the medicine to school to take at six because it will be known.”
Rejection, discrimination, and 
blame
“Sometimes when you tell people, they will know that you have AIDS. Then after one year or so they 
go and misbehave outside. Then they get AIDS, and they come around and say it’s you who brought it 
on them and infected them. They get angry at you forever.”
“It is important to keep it secret because when everybody knows, they will be just abusing your name.”
Growing tired of taking medicines “You become tired. Some of them are bitter, they are many. If there is medicine that can be swallowed 
once per day, it would be better.”
Not knowing why they are taking 
medicines
“I would take for a week and miss two days because I didn’t know why I was taking it… But after I 
was told why, I became strict in taking.”
Delaying in front of others “We are many in the house, and it is only the parents who know, so if they are not there and the others 
see me removing these drugs, they will be anxious to know what they are for and why I am taking. So it 
forces me to wait if they are around, and at times, I even forget and the time for taking (the drugs) 
passes. I swallow late.”
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